| Project/Area Number |
23659827
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Plastic surgery
|
|---|
| Research Institution | University of Tsukuba |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ISHIGE Kazunori 筑波大学, 医学医療系, 講師 (20597918)
SHODA Junichi 筑波大学, 医学医療系, 教授 (90241827)
TAKEUCHI Kaoru 筑波大学, 医学医療系, 准教授 (00192162)
KAWAKAMI Koji 京都大学, 医学系研究科, 教授 (70422318)
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 悪性黒色腫 / サイトカイン / 受容体 / 標的治療 / バイオ療法 |
|---|
| Research Abstract |
Interleukin-4 receptor (IL-4R) is highly expressed on the surface of various human solid tumors including head and neck squamous cell carcinoma (HNSCC). Recently, we designed a novel IL-4R-lytic hybrid peptide composed of a binding peptide to IL-4R and a cell-lytic peptide. We confirmed the antitumor activity of the IL-4R-lytic hybrid peptide as a novel molecular-targeted therapy in several kinds of cancers. Malignant melanoma is a challenging cancer with poorer survival outcome. In addition, oral cavity cancer is also a challenging cancer in its advanced cases. In this study, we evaluated the antitumor activity of the IL-4R-lytic hybrid peptide as a novel molecular-targeted therapy in malignant melanoma and oral cavity cancers. IL-4R was expressed in oral cavity cancer cell lines, but not in a human normal keratinocyte. IL-4R in oral cavity cancer tissue was higher compared to that in normal epithelial tissue. The results revealed the antitumor activity of the IL-4R-lytic hybrid peptide against oral cavity cancers in a dose-dependent manner using the in vitro and in vivo experiments. However, we did not confirm the antitumor activity against malignant melanoma.
|
